Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non‐executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.
“His track record of strong leadership and board experience in the pharmaceutical industry will be hugely valuable as we position ourselves as a world‐leading drug development and manufacturing organization,” said Mark Egerton, Ph.D., Quotient CEO. “Claes has extensive experience supporting high‐growth businesses such as Quotient across multiple geographies.”
Since 2016, Glassell has been a director of the board at Cambrex and currently serves as nonexecutive chairman of the board of LSNE Contract Manufacturing. From 2011 to 2015, he was CEO of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals.
Previously, he held senior positions and served on the boards of several public and private companies, including Vitrolife AB, Cellartis AB, Nobel Chemicals, and Cerus.
“I am excited to join Quotient at this important juncture following the recent investment by Permira,” said Glassell. “Quotient Sciences and its disruptive approach to drug development have created a unique business model that truly accelerates drug development. I welcome the
opportunity to work with an outstanding management team, supported by a strong board and investors, to help Quotient through its next stage of growth.”
“I am delighted that Claes has accepted this position,” said Mubasher Sheikh, partner and head of healthcare at Permira. “Claes brings a set of highly relevant skills and experience to the board, and I look forward to working with him and the executive team."